Cardiovascular events after cancer immunotherapy as oncologic emergencies: Analyses of 610 head and neck cancer patients treated with immune checkpoint inhibitors.
Cielito C Reyes-GibbyAiham Z QdaisatRenata FerrarottoAnecita FadolJason J BischofChristopher J CoyneDemis N LipeEhab Y HannaSanjay S SheteJun-Ichi AbeSai-Ching J YeungPublished in: Head & neck (2023)
The use of ICI in HNC is still expanding and the spectrum of delayed manifestation of ICI-induced cardiovascular toxicities is yet to be fully defined in HNC survivors.